Who Paid My Doc
Amy Foster
Registered Nurse, Nephrology Tulsa, OK Nurse Practitioner
NPI 1699847764 CMS profile 10527528
2000 S Wheeling Ave, Ste 510, Tulsa, OK 74104
General payments
$703
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Amy Foster of Tulsa, OK is reported in the CMS Open Payments database as having received $703 across 29 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $209 | 6 | |
| 2024 | General | $100 | 4 | |
| 2023 | General | $46 | 3 | |
| 2022 | General | $248 | 10 | |
| 2021 | General | $100 | 6 |
Beside peers
- Amy Foster
- Oklahoma median
- Middle half of Oklahoma
- National median
In program year 2025, general payments to Amy Foster were reported at $209. Among 11,599 Oklahoma profiles paid that year, the median was $171 and the middle half received between $51 and $608.
Show as a table
| Year | Amy Foster | Oklahoma median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $175 | $48–$674 | $163 |
| 2020 | $0 | $117 | $34–$396 | $114 |
| 2021 | $100 | $133 | $34–$473 | $132 |
| 2022 | $248 | $153 | $43–$574 | $149 |
| 2023 | $46 | $166 | $45–$588 | $160 |
| 2024 | $100 | $170 | $48–$602 | $164 |
| 2025 | $209 | $171 | $51–$608 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 141 drugsPart D claims
14,868
Drug cost
$1,720,813
Branded share of claims
33.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 512 | $493,348 | |
| Jardiance Empagliflozin | Brand | 530 | $328,388 | |
| Mounjaro Tirzepatide | Brand | 227 | $244,858 | |
| Eliquis Apixaban | Brand | 303 | $183,471 | |
| Entresto Sacubitril/Valsartan | Brand | 81 | $57,352 | |
| Myrbetriq Mirabegron | Brand | 86 | $40,738 | |
| Humulin R U-500 Kwikpen Insulin Regular, Human | Brand | 24 | $29,931 | |
| Alogliptin Alogliptin Benzoate | Brand | 131 | $22,918 | |
| Levemir Flexpen Insulin Detemir | Brand | 119 | $21,781 | |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 228 | $19,837 |
The 10 drugs with the highest cost, of 141 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 476 Part D prescribers listed as Registered Nurse; they describe a distribution and say nothing about conduct.
Records
29 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Registered Nurse, Nephrology in Oklahoma
Related records
Registered Nurse, Nephrology in Oklahoma
Practitioners in the same specialty and state, ranked by reported value.
All Registered Nurse, Nephrology
Everyone recorded under this specialty, nationwide.
Doctors in Oklahoma
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.